参考文献/References:
[1] Hoit BD,Shao Y,Gabel M. Left atrial systolic and diastolic function accompanying chronic rapid pacing-induced atrial failure[J]. Am J Physiol,1998,275(1):183-189.
[2] Bisbal F,Baranchuk A,Braunwald E,et al. Atrial failure as a clinical entity:JACC Review Topic of the Week[J]. J Am Coll Cardiol ,2020,75(2):222-232.
[3] Sherif HM. The developing pulmonary veins and left atrium:implications for ablation strategy for atrial fibrillation[J]. Eur J Cardiothorac Surg,2013,44(5):792-799.
[4] Karim N,Ho SY,Nicol E,et al. The left atrial appendage in humans:structure,physiology,and pathogenesis[J]. Europace ,2020,22(1):5-18.
[5] Triposkiadis F,Pieske B,Butler J,et al. Global left atrial failure in heart failure[J]. Eur J Heart Fail,2016,18(11):1307-1320.
[6] Das A. Electrocardiographic features:various atrial site pacing[J]. Indian Heart J ,2017,69(5):675-680.
[7] Pambrun T,Derval N,Duchateau J,et al. Sinus node exit,crista terminalis conduction,interatrial connection,and wavefront collision:Key features of human atrial activation in sinus rhythm[J]. Heart Rhythm ,2022,19(5):701-709.
[8] Nakagawa Y,Nishikimi T,Kuwahara K. Atrial and brain natriuretic peptides:hormones secreted from the heart[J]. Peptides ,2019,111:18-25.
[9] Goetze JP,Bruneau BG,Ramos HR,et al. Cardiac natriuretic peptides[J]. Nat Rev Cardiol ,2020,17(11):698-717.
[10] Goldberger JJ,Arora R,Buckley U,et al. Autonomic nervous system dysfunction:JACC Focus Seminar[J]. J Am Coll Cardiol ,2019,73(10):1189-1206.
[11] Ghitani N,Chesler AT. The anatomy of the baroreceptor reflex[J]. Cell Rep,2019,29(8):2121-2122.
[12] Litviňuková M,Talavera-López C,Maatz H,et al. Cells of the adult human heart[J]. Nature ,2020,588(7838):466-472.
[13] Goette A,Kalman JM,Aguinaga L,et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies:Definition,characterization,and clinical implication[J]. Heart Rhythm,2017,14(1):e3-e40.
[14] Aguero J,Galan-Arriola C,Fernandez-Jimenez R,et al. Atrial infarction and ischemic mitral regurgitation contribute to post-MI remodeling of the left atrium[J]. J Am Coll Cardiol ,2017,70(23):2878-2889.
[15] Reginauld SH,Cannone V,Iyer S,et al. Differential regulation of ANP and BNP?in?acute decompensated heart failure:deficiency of ANP[J]. JACC Heart Fail ,2019,7(10):891-898.
[16] Tripathi R,Wang D,Sullivan R,et al. Depressed corin levels indicate early systolic dysfunction before increases of atrial natriuretic peptide/B-type natriuretic peptide and heart failure development[J]. Hypertension ,2016,67(2):362-367.
[17] Zucker IH. Novel mechanisms of sympathetic regulation in chronic heart failure[J]. Hypertension ,2006,48(6):1005-1011.
[18] Floras JS,Ponikowski P. The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction[J]. Eur Heart J ,2015,36(30):1974-1982.
[19] Brack KE. The heart’s ’little brain’ controlling cardiac function in the rabbit[J]. Exp Physiol ,2015,100(4):348-353.
[20] 陈楚云,杨颖,张岩. 心房衰竭：新的临床综合征?[J]. 临床心血管病杂志,2021,37(10):882-886.
[21] Maron BJ,Towbin JA,Thiene G,et al. Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology,Heart Failure and Transplantation Committee,Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups,and Council on Epidemiology and Prevention[J]. Circulation ,2006,113(14):1807-1816.
[22] Sugumar H,Nanayakkara S,Prabhu S,et al. Pathophysiology of atrial fibrillation and heart failure:dangerous interactions[J]. Cardiol Clin ,2019,37(2):131-138.
[23] Paulus WJ,Tsch?pe C. A novel paradigm for heart failure with preserved ejection fraction:comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation[J]. J Am Coll Cardiol ,2013,62(4):263-271.
[24] Zakeri R,Moulay G,Chai Q,et al. Left atrial remodeling and atrioventricular coupling in a canine model of early heart failure with preserved ejection fraction[J]. Circ Heart Fail ,2016,9(10):e003238.
[25] Smolarek D,Grucha?a M,Sobiczewski W. Echocardiographic evaluation of right ventricular systolic function:The traditional and innovative approach[J]. Cardiol J ,2017,24(5):563-572.
[26] Egom EE,Feridooni T,Pharithi RB,et al. A natriuretic peptides clearance receptor’s agonist reduces pulmonary artery pressures and enhances cardiac performance in preclinical models:new hope for patients with pulmonary hypertension due to left ventricular heart failure[J]. Biomed Pharmacother ,2017,93:1144-1150.
[27] Kwok CS,Rashid M,Beynon R,et al. Prolonged PR interval,first-degree heart block and adverse cardiovascular outcomes:a systematic review and meta-analysis[J]. Heart ,2016,102(9):672-680.
[28] Tiffany Win T,Ambale Venkatesh B,Volpe GJ,et al. Associations of electrocardiographic P-wave characteristics with left atrial function,and diffuse left ventricular fibrosis defined by cardiac magnetic resonance:the PRIMERI Study[J]. Heart Rhythm,2015,12(1):155-162.
[29] Schumacher K,Dagres N,Hindricks G,et al. Characteristics of PR interval as predictor for atrial fibrillation:association with biomarkers and outcomes[J]. Clin Res Cardiol ,2017,106(10):767-775.
[30] Olsen FJ,Bertelsen L,Vejlstrup N,et al. Association between four-dimensional echocardiographic left atrial measures and left atrial fibrosis assessed by left atrial late gadolinium enhancement[J]. Eur Heart J Cardiovasc Imaging ,2022,24(1):152-161.
[31] Cau R,Bassareo P,Suri JS,et al. The emerging role of atrial strain assessed by cardiac MRI in different cardiovascular settings:an up-to-date review[J]. Eur Radiol ,2022,32(7):4384-4394.
[32] Tsang TS,Barnes ME,Abhayaratna WP,et al. Effects of quinapril on left atrial structural remodeling and arterial stiffness[J]. Am J Cardiol ,2006,97(6):916-920.
[33] Gerdts E,Wachtell K,Omvik P,et al. Left atrial size and risk of major cardiovascular events during antihypertensive treatment:losartan intervention for endpoint reduction in hypertension trial[J]. Hypertension ,2007,49(2):311-316.
[34] Zhang Y,Zhang L,Fan X,et al. Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/β-catenin and Jak2/Stat3 pathways[J]. Biomed Pharmacother ,2019,113:108780.
[35] Verbrugge FH,Omote K,Reddy YNV,et al. Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality[J]. Eur Heart J ,2022,43(20):1941-1951.
[36] Kuwahara K. The natriuretic peptide system in heart failure:diagnostic and therapeutic implications[J]. Pharmacol Ther ,2021,227:107863.
[37] Liu Y,Lv H,Tan R,An X,Niu XH,Liu YJ,et al. Platelets promote Ang Ⅱ (angiotensin II)-induced atrial fibrillation by releasing TGF-β1 (transforming growth factor-β1) and interacting with fibroblasts[J]. Hypertension ,2020,76(6):1856-1867.